Agios Pharmaceuticals Inc.
AGIO
NGS
Sector: Healthcare
Industry: Biotechnology
24.54
USD
0.18
(0.72%)
Optionable: Yes Market Cap: 1,358 M 90-day average vol: 344,878
Previous close: 24.36 Open: 24.43 Bid: 24.34 Ask: 24.81
52 week range
21.07 31.87
Last updated: Thursday 28th September 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordFinancials
AGIO Income Statement
Annual
| Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| AccruedPreferredStockDividends | 4 M | |||||||||
| Basic EPS from continuing operations | -4.77 | -5.9 | -4.23 | |||||||
| Basic EPS total | -0.76 | -4.74 | 26.55 | -4.23 | ||||||
| Basic weighted shares outstanding | 15 M | 34 M | 37 M | 39 M | 47 M | 57 M | 60 M | 69 M | 60 M | 55 M |
| BasicDiscontinuousOperations | 0.03 | 32.45 | ||||||||
| Cost of sales | -72000.0 | -83000.0 | -135000.0 | -70000.0 | -1 M | -1 M | -3 M | -2 M | ||
| Depreciation | -1 M | -1 M | -3 M | -6 M | -6 M | -7 M | -8 M | -9 M | -9 M | -8 M |
| DepreciationAndAmortization | -1 M | -1 M | -3 M | -6 M | -6 M | -7 M | -8 M | -9 M | -9 M | -8 M |
| Diluted EPS total | -2.83 | -1.59 | -3.15 | -5.07 | -6.75 | -6.03 | -6.86 | -4.74 | 26.55 | -4.23 |
| Diluted normalized net income/share | -4.77 | -5.9 | -4.23 | |||||||
| Diluted weighted shares outstanding | 14 M | 34 M | 37 M | 39 M | 47 M | 57 M | 60 M | 69 M | 60 M | 55 M |
| DilutedDiscontinuousOperations | 0.03 | 32.45 | ||||||||
| GainOnSaleOfBusiness | 7 M | |||||||||
| GainOnSaleOfPPE | 128 M | |||||||||
| GainOnSaleOfSecurity | 16000.0 | -261000.0 | ||||||||
| GeneralAndAdministrativeExpense | 10 M | 19 M | 36 M | 51 M | -6 M | -11 M | ||||
| Gross operating profit | 26 M | 65 M | 59 M | 70 M | 43 M | 93 M | 117 M | 118 M | 500000.0 | 13 M |
| Income before tax | -39 M | -54 M | -118 M | -198 M | -315 M | -346 M | -301 M | -329 M | -357 M | -232 M |
| Income taxes | 579000.0 | -426000.0 | ||||||||
| Interest income | 55000.0 | 203000.0 | 968000.0 | 3 M | 6 M | 16 M | 15 M | 7 M | 836000.0 | 141 M |
| MiscOtherSpecialCharges | 38 M | 32 M | 62 M | 14 M | 7 M | |||||
| Net income from total operations | -39 M | -54 M | -118 M | -198 M | -315 M | -346 M | -411 M | -329 M | -357 M | -232 M |
| NetIncomeCommonStockholders | -44 M | -54 M | -118 M | -198 M | -315 M | -346 M | -411 M | -329 M | -357 M | -232 M |
| NetIncomeContinuousOperations | -39 M | -54 M | -118 M | -198 M | -315 M | -346 M | -411 M | -329 M | -357 M | -232 M |
| NetIncomeDiscontinuousOperations | 2 M | 1,961 M | ||||||||
| NetIncomeFromOtherGainsLosses | -18 M | |||||||||
| NetNonOperatingInterestIncomeExpense | 55000.0 | 203000.0 | 968000.0 | 3 M | 6 M | 16 M | 15 M | 7 M | 836000.0 | 141 M |
| Operating income | -39 M | -54 M | -119 M | -201 M | -321 M | -362 M | -426 M | -336 M | -378 M | -389 M |
| Operating income before depreciation (EBITDA) | -37 M | -52 M | -114 M | -192 M | -308 M | -343 M | -288 M | -308 M | -331 M | -214 M |
| OperatingExpense | -64 M | -119 M | -178 M | -271 M | -364 M | 455 M | 543 M | 336 M | 378 M | 402 M |
| Other income net | -16000.0 | 261000.0 | -38 M | -32 M | -62 M | -14 M | -7 M | |||
| Other special charges | -7 M | -10 M | ||||||||
| OtherGandA | 10 M | 19 M | 36 M | 51 M | -6 M | -11 M | ||||
| OtherOperatingExpenses | -364 M | -457 M | -15 M | -15 M | -15 M | -15 M | ||||
| OtherunderPreferredStockDividend | 4 M | |||||||||
| PreferredStockDividends | 4 M | |||||||||
| RentAndLandingFees | 10 M | 19 M | 36 M | 51 M | -6 M | -11 M | ||||
| Research & development expense | 55 M | 100 M | 142 M | 220 M | 293 M | 341 M | 411 M | 221 M | 257 M | 280 M |
| ResearchExpense | 55 M | 100 M | 142 M | 220 M | 293 M | 341 M | 411 M | 221 M | 257 M | 280 M |
| SalariesAndWages | -3 M | -12 M | -32 M | -42 M | -48 M | -73 M | -72 M | -62 M | -54 M | -49 M |
| Selling Gen & administrative expense | 10 M | 19 M | 36 M | 51 M | 71 M | 114 M | 132 M | 115 M | 121 M | 122 M |
| SellingAndMarketingExpense | 71 M | 114 M | 132 M | 115 M | 121 M | 122 M | ||||
| SellingExpense | 71 M | 114 M | 132 M | 115 M | 121 M | 122 M | ||||
| Special income/charges | 7 M | 10 M | ||||||||
| Total Income available for interest expense (EBIT) | -39 M | -54 M | -118 M | -198 M | -315 M | -346 M | -301 M | -329 M | -357 M | -232 M |
| Total common shares outstanding | 32 M | 37 M | 38 M | 42 M | 57 M | 58 M | 69 M | 70 M | 55 M | 55 M |
| Total net income | -39 M | -54 M | -118 M | -198 M | -315 M | -346 M | -411 M | -329 M | -357 M | -232 M |
| Total ordinary shares | 56 M | 56 M | 56 M | 56 M | 56 M | 56 M | 56 M | 56 M | 56 M | 56 M |
| Total revenues | 26 M | 65 M | 59 M | 70 M | 43 M | 94 M | 118 M | 121 M | 500000.0 | 14 M |
| TotalExpenses | -65 M | -120 M | -178 M | -271 M | -364 M | 454 M | 542 M | 336 M | 378 M | 400 M |
| TotalRevenue | 26 M | 65 M | 59 M | 70 M | 43 M | 94 M | 118 M | 203 M | 500000.0 | 14 M |
Call: 1-877-778-8358
Welcome! I'm Ankur, the founder/CEO of MarketXLS. With over six years of experience, I've helped 2500+ customers implement personalized investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and Templates.
Get started today
Get started today